Literature DB >> 11163124

Repeated ethanol administration induces short- and long-term changes in enkephalin and dynorphin tissue concentrations in rat brain.

S Lindholm1, K Ploj, J Franck, I Nylander.   

Abstract

Recently, we have shown that rats repeatedly treated with ethanol and/or cocaine have decreased kappa-opioid receptor mRNA levels in the mesolimbic system. The aim of the present study was to investigate the short- and long-term effects of repeated ethanol administration on opioid peptide concentrations in brain tissue of male Sprague-Dawley rats. Dynorphin B (1-13) (Dyn B) and Met-enkephalinArg(6)Phe(7) (MEAP), endogenous ligands to kappa- and delta-opioid receptors, respectively, were measured using radioimmunoassays. The rats were given either ethanol [intraperitoneal (ip), twice daily, 2 g/kg bw/dose] or saline for 13 consecutive days. Thirty minutes after the last ethanol dose on Day 13, the Dyn B tissue concentration was significantly decreased in the cingulate cortex. The MEAP tissue concentration was decreased in the hippocampus 5 days after the last ethanol injection as compared to saline-treated controls. Furthermore, the Dyn B and the MEAP concentrations were increased in the periaqueductal grey area (PAG) at this time point. Of particular interest were the significant increases in Dyn B tissue concentrations found in the nucleus accumbens (NAcc) at 30 min and at 21 days after the last ethanol dose. The results suggest that repeated ethanol administration induces both short- and long-term changes in the tissue concentrations of opioids in certain brain regions associated with motivation and reward.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11163124     DOI: 10.1016/s0741-8329(00)00118-x

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  60 in total

1.  The role of endogenous dynorphin in ethanol-induced state-dependent CPP.

Authors:  Khanh Nguyen; Andy Tseng; Paul Marquez; Abdul Hamid; Kabirullah Lutfy
Journal:  Behav Brain Res       Date:  2011-10-29       Impact factor: 3.332

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 3.  Overconsumption of dietary fat and alcohol: mechanisms involving lipids and hypothalamic peptides.

Authors:  Sarah F Leibowitz
Journal:  Physiol Behav       Date:  2007-03-30

Review 4.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

Review 5.  Running is rewarding and antidepressive.

Authors:  Stefan Brené; Astrid Bjørnebekk; Elin Aberg; Aleksander A Mathé; Lars Olson; Martin Werme
Journal:  Physiol Behav       Date:  2007-05-21

Review 6.  Natural rewards, neuroplasticity, and non-drug addictions.

Authors:  Christopher M Olsen
Journal:  Neuropharmacology       Date:  2011-04-01       Impact factor: 5.250

7.  Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.

Authors:  Brendan M Walker; George F Koob
Journal:  Neuropsychopharmacology       Date:  2007-05-02       Impact factor: 7.853

8.  Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms.

Authors:  Xiu Liu; Friedbert Weiss
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 9.  The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.

Authors:  David Mysels; Maria A Sullivan
Journal:  Am J Addict       Date:  2009 Jul-Aug

10.  The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors.

Authors:  Jessica L Kissler; Sunil Sirohi; Daniel J Reis; Heiko T Jansen; Raymond M Quock; Daniel G Smith; Brendan M Walker
Journal:  Biol Psychiatry       Date:  2013-04-21       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.